Skip to main content
SpringerLink
Log in

Diagnostic Applications of Nuclear Medicine: Esophageal Cancers

Nuclear Oncology

  • 155 Accesses

Abstract

Esophageal cancer is the eighth most commonly diagnosed malignancy worldwide. This chapter will review the epidemiology, environmental factors, genetic predisposition, and underlying biomolecular changes of the disease. The staging of esophageal cancer will be reviewed as well as the roles of conventional diagnostic imaging and nuclear imaging in this staging. Finally, the efficacy of these modalities in assessing response to the various treatments described in the chapter and in the long term surveillance for disease recurrence will be addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Abbreviations

[18F]FDG:

2-Deoxy-2-[18F]fluoro-d-glucose

AJCC:

American Joint Committee on Cancer

APC:

Gene encoding for adenomatous polyposis coli

c-myc:

Gene encoding for a transcription factor (a multifunctional, nuclear phosphoprotein involved in cell cycle progression, apoptosis, and cellular transformation)

CT:

X-ray computed tomography

erb B-2:

Gene encoding for the receptor tyrosine-protein kinase erbB-2 (also known as CD340 or proto-oncogene Neu)

EUS:

Endoscopic ultrasonography

GERD:

Gastrointestinal reflux disease

GI:

Gastrointestinal

Gy:

Gray unit (ionizing radiation dose in the International System of Units, corresponding to the absorption of one joule of radiation energy per kilogram of matter)

HPV:

Human papillomavirus

M:

Metastasis status according to the AJCC/UICC TNM staging system

MBq:

Mega-Becquerel (106 Becquerel)

MIP:

Maximum intensity projection

MR:

Magnetic resonance

N:

Lymph node status according to the AJCC/UICC TNM staging system

p16:

Protein encoded by the CDKN2A gene (also known as cyclin-dependent kinase inhibitor 2A or multiple tumor suppressor 1)

p53:

Tumor protein p53, also known as cellular tumor antigen p53, phosphoprotein p53, tumor suppressor p53, antigen NY-CO-13, or transformation-related protein 53 (TRP53)

PERCIST:

Positron emission tomography response criteria in solid tumors

PET:

Positron emission tomography

PET/CT:

Positron emission tomography/computed tomography

PET/MR:

Positron emission tomography/magnetic resonance

Rb:

Gene encoding for the retinoblastoma protein

RECIST:

Response evaluation criteria in solid tumors

SSC:

Squamous cell carcinoma

SUR:

Standardized uptake ratio (ratio of tumor SUV and blood pool SUV)

SUV:

Standardized uptake value

SUVmax :

Standardized uptake value at point of maximum

T:

Tumor status according to the AJCC/UICC TNM staging system

UICC:

Union Internationale Contre le Cancer (International Union Against Cancer)

US:

Ultrasonography

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7.

    Article  PubMed  Google Scholar 

  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87.

    Article  PubMed  Google Scholar 

  3. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev. 2010;19(6):1468.

    Article  PubMed  Google Scholar 

  4. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut. 2005;54 Suppl 1:i1–5.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Gholipour C, Shalchi RA, Abbasi M. A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus. 2008;21(4):322.

    Article  CAS  PubMed  Google Scholar 

  6. Shuyama K, Castillo A, Aguayo F, Sun Q, Khan N, Koriyama C, Akiba S. Human papillomavirus in high- and low-risk areas of oesophageal squamous cell carcinoma in China. Br J Cancer. 2007;96(10):1554.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Engel LS, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95(18):1404.

    Article  PubMed  Google Scholar 

  8. Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119(6):1149–58.

    Article  PubMed  Google Scholar 

  9. Chang-Claude J, Becher H, Blettner M, Qiu S, Yang G, Wahrendorf J. Familial aggregation of oesophageal cancer in a high incidence area in China. Int J Epidemiol. 1997;26(6):1159.

    Article  CAS  PubMed  Google Scholar 

  10. Chak A, Lee T, Kinnard MF, Brock W, Faulx A, Willis J, Cooper GS, Sivak Jr MV, Goddard KA. Familial aggregation of Barrett’s oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut. 2002;51(3):323.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–52.

    Article  CAS  PubMed  Google Scholar 

  12. Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, Asomaning K, Su L, Nishioka NS, Tanabe KK, Christiani DC. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res. 2008;14(10):3216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kuwano H, et al. Genetic alterations in esophageal cancer. Surg Today. 2005;35(1):7–18.

    Article  PubMed  Google Scholar 

  14. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, Reid BJ. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet. 1999;22(1):106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Meltzer SJ. The molecular biology of esophageal carcinoma. Recent Results Cancer Res. 1996;142:1.

    Article  CAS  PubMed  Google Scholar 

  16. Yoon YC, et al. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection - prospective study. Radiology. 2003;227:764–70.

    Article  PubMed  Google Scholar 

  17. Rosch T. Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am. 1995;5(3):537.

    CAS  PubMed  Google Scholar 

  18. Catalano MF, Sivak Jr MV, Rice T, Gragg LA, Van Dam J. Endosonographic features predictive of lymph node metastasis. Gastrointest Endosc. 1994;40(4):442.

    Article  CAS  PubMed  Google Scholar 

  19. Kato H, Miyazaki T, Nakajima M, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005;103(1):148–56.

    Article  PubMed  Google Scholar 

  20. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98(3):547.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Manabe O, et al. Diagnostic accuracy of lymph node metastasis depends on metabolic activity of the primary lesion in thoracic squamous esophageal cancer. J Nucl Med. 2013;54(5):670–6.

    Article  CAS  PubMed  Google Scholar 

  22. Pierre AM, et al. Detection of distant metastases in esophageal cancer with F-18 FDG PET. J Nucl Med. 2004;45(6):980–7.

    Google Scholar 

  23. Chatterton BE, et al. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009;36(3):354–61.

    Article  CAS  PubMed  Google Scholar 

  24. Wallace MB, et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg. 2002;74(4):1026–32.

    Article  PubMed  Google Scholar 

  25. Yasuda, et al. The impact of F-18 FDG PET positive lymph nodes on postoperative recurrence and survival in resectable thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19:652–60.

    Article  PubMed  Google Scholar 

  26. Butof, et al. Prognostic value of pretherapeutic tumor-to-blood standardized uptake ratio in patients with esophageal carcinoma. J Nucl Med. 2015;56(8):1150–6.

    Article  CAS  PubMed  Google Scholar 

  27. Tixier, et al. Intratumor heterogeneity characterized by textural features on baseline F-18 FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52(3):369–78.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Lee G, et al. Clinical implication of PET/MR imaging in preoperative esophageal cancer staging: comparison with PET/CT, endoscopic ultrasonography, and CT. J Nucl Med. 2014;55(8):1242–7.

    Article  PubMed  Google Scholar 

  29. Gebski, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.

    Article  CAS  PubMed  Google Scholar 

  30. Kim MK, Ryu JS, Kim SB, et al. Value of complete metabolic response by F-18-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer. 2007;43:1385–91.

    Article  PubMed  Google Scholar 

  31. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  PubMed  Google Scholar 

  33. Yanagawa M, et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med. 2012;53(6):872–80.

    Article  CAS  PubMed  Google Scholar 

  34. Omloo JM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246:992–1000.

    Article  PubMed  Google Scholar 

  35. Mariette C, et al. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003;97:1616–23.

    Article  PubMed  Google Scholar 

  36. Abate E, et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg. 2010;210:428–35.

    Article  PubMed  Google Scholar 

  37. Goense L, et al. Diagnostic performance of F-18 FDG PET and PET/CT for the detection of recurrent esophageal cancer after treatment with curative intent: a systematic review and meta-analysis. J Nucl Med. 2015;56(7):995–1002.

    Article  PubMed  Google Scholar 

  38. Kubota K, et al. Surgical therapy and chemoradiotherapy for postoperative recurrent esophageal cancer. Hepatogastroenterology. 2013;60:1961–5.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA

    Christopher G. Sakellis, Heather A. Jacene & Annick D. Van den Abbeele

  2. Department of Radiology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA, 02215, USA

    Christopher G. Sakellis, Heather A. Jacene & Annick D. Van den Abbeele

  3. Harvard Medical School, Boston, MA, USA

    Christopher G. Sakellis, Heather A. Jacene & Annick D. Van den Abbeele

  4. Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA

    Christopher G. Sakellis, Heather A. Jacene & Annick D. Van den Abbeele

  5. Tumor Imaging Metrics Core, Dana-Farber/Harvard Cancer Center, 450 Brookline Avenue, Boston, MA, 02215, USA

    Christopher G. Sakellis, Heather A. Jacene & Annick D. Van den Abbeele

Authors
  1. Christopher G. Sakellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heather A. Jacene
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Annick D. Van den Abbeele
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Attending Emeritus, Memorial Sloan-Kettering Cancer Center Dept. Radiology, New York, New York, USA

    H. William Strauss

  2. Professor Emeritus, University of Pisa, Pisa, Italy

    Giuliano Mariani

  3. Associate Professor and Director of Nuclear Medicine, University of Pisa, Pisa, Italy

    Duccio Volterrani

  4. Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

    Steven M. Larson

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing AG

About this entry

Cite this entry

Sakellis, C.G., Jacene, H.A., Van den Abbeele, A.D. (2016). Diagnostic Applications of Nuclear Medicine: Esophageal Cancers. In: Strauss, H., Mariani, G., Volterrani, D., Larson, S. (eds) Nuclear Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-26067-9_41-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26067-9_41-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Online ISBN: 978-3-319-26067-9

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Diagnostic Applications of Nuclear Medicine: Esophageal Cancers
    Published:
    26 July 2022

    DOI: https://doi.org/10.1007/978-3-319-26067-9_41-2

  2. Original

    Diagnostic Applications of Nuclear Medicine: Esophageal Cancers
    Published:
    08 October 2016

    DOI: https://doi.org/10.1007/978-3-319-26067-9_41-1

Search

Navigation